Nexsen Launches Clinical Trial for Group B Streptococcus Bacteria Detection Device; Shares Fall 7%

MT Newswires Live

Oct 21, 2025

Nexsen (ASX:NXN) started a clinical trial for the GBS Rapid Sensor diagnostic device for the detection of Group B Streptococcus bacteria in expectant mothers, according to a Tuesday Australian bourse filing.

The trial was registered with the Australia and New Zealand Clinical Trials Register, and approved by the Royal Children's Hospital Melbourne Human Research Ethics Committee, the filing said. An initial 1,000 investigational devices were delivered to the clinical trial team.

The sensor is designed to provide real time, point of care testing during labor.

Participants are being enrolled and tested at the labor wards of the Northern Hospital, Epping in Victoria.

Nexsen's shares fell 7% in recent trading on Tuesday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2577817665"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2577817665\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2577817665?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-21 12:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2577817665","market":"nz","top_or_hot":-1,"title":"Nexsen Launches Clinical Trial for Group B Streptococcus Bacteria Detection Device; Shares Fall 7%","media":"MT Newswires Live","content":"<html><body><p> Nexsen (ASX:NXN) started a clinical trial for the GBS Rapid Sensor diagnostic device for the detection of Group B Streptococcus bacteria in expectant mothers, according to a Tuesday Australian bourse filing.</p><p>The trial was registered with the <a href=\"https://laohu8.com/S/AN3PF.AU\">Australia and New Zealand</a> Clinical Trials Register, and approved by the Royal Children's Hospital Melbourne Human Research Ethics Committee, the filing said. An initial 1,000 investigational devices were delivered to the clinical trial team.</p><p>The sensor is designed to provide real time, point of care testing during labor.</p><p>Participants are being enrolled and tested at the labor wards of the Northern Hospital, Epping in <a href=\"https://laohu8.com/S/VCCTF\">Victoria</a>.</p><p>Nexsen's shares fell 7% in recent trading on Tuesday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nexsen Launches Clinical Trial for Group B Streptococcus Bacteria Detection Device; Shares Fall 7%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNexsen Launches Clinical Trial for Group B Streptococcus Bacteria Detection Device; Shares Fall 7%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-10-21 12:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Nexsen (ASX:NXN) started a clinical trial for the GBS Rapid Sensor diagnostic device for the detection of Group B Streptococcus bacteria in expectant mothers, according to a Tuesday Australian bourse filing.</p><p>The trial was registered with the <a href=\"https://laohu8.com/S/AN3PF.AU\">Australia and New Zealand</a> Clinical Trials Register, and approved by the Royal Children's Hospital Melbourne Human Research Ethics Committee, the filing said. An initial 1,000 investigational devices were delivered to the clinical trial team.</p><p>The sensor is designed to provide real time, point of care testing during labor.</p><p>Participants are being enrolled and tested at the labor wards of the Northern Hospital, Epping in <a href=\"https://laohu8.com/S/VCCTF\">Victoria</a>.</p><p>Nexsen's shares fell 7% in recent trading on Tuesday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2577817665","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2577817665","pubTimestamp":1761020360,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Nexsen  started a clinical trial for the GBS Rapid Sensor diagnostic device for the detection of Group B Streptococcus bacteria in expectant mothers, according to a Tuesday Australian bourse filing.The trial was registered with the Australia and New Zealand Clinical Trials Register, and approved by the Royal Children's Hospital Melbourne Human Research Ethics Committee, the filing said. An initial 1,000 investigational devices were delivered to the clinical trial team.The sensor is designed to provide real time, point of care testing during labor.Participants are being enrolled and tested at the labor wards of the Northern Hospital, Epping in Victoria.Nexsen's shares fell 7% in recent trading on Tuesday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","XKO.AU":"标普/澳交所 300指数","XJO.AU":"标普/澳交所 200指数","XAO.AU":"标普/澳交所 普通股指数","NXN.AU":"Nexsen Limited"},"translate_title":"Nexsen启动B组链球菌检测装置临床试验；股价下跌7%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XKO.AU":0.8,"XAO.AU":0.8,"XJO.AU":0.8,"NXN.AU":1},"content_text":"Nexsen (ASX:NXN) started a clinical trial for the GBS Rapid Sensor diagnostic device for the detection of Group B Streptococcus bacteria in expectant mothers, according to a Tuesday Australian bourse filing.The trial was registered with the Australia and New Zealand Clinical Trials Register, and approved by the Royal Children's Hospital Melbourne Human Research Ethics Committee, the filing said. An initial 1,000 investigational devices were delivered to the clinical trial team.The sensor is designed to provide real time, point of care testing during labor.Participants are being enrolled and tested at the labor wards of the Northern Hospital, Epping in Victoria.Nexsen's shares fell 7% in recent trading on Tuesday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}